Outcomes in COVID-19 Patients with Pneumonia Treated with High-Flow Oxygen Therapy and Baricitinib-Retrospective Single-Center Study.

Dušanka Obradović Milica PopovićMaja BanjacJelena BulajićVladimir ĐurovićIvana UroševićAleksandra Milovančev

Published in: Life (Basel, Switzerland) (2023)

Treatment with baricitinib in addition to SOC was associated with reduced mortality and a lower prevalence of transfer to the ICU in hospitalized patients with COVID-19 pneumonia treated with high-flow oxygen non-invasive therapy.

Keyphrases

risk factors
sars cov
intensive care unit
cross sectional
type diabetes
adipose tissue
cell therapy
newly diagnosed
metabolic syndrome
mechanical ventilation
insulin resistance
weight loss